Патогенетичне обґрунтування діагностики та корекції кардіометаболічних порушень у хворих на гіпертонічну хворобу з цукровим діабетом 2-го типу

47. Associations of visceral and subcutaneous adipose tissue mass with markers of cardiometabolic risk in obese adults: observations from the Dallas heart study / I. Neeland, C. R. Ayers, A. Rohatgi et al. // J. Am. Coll. Cardiol. - 2012. - 59(13s1). - Р. е1786. - Doi : 10.1016/S0735-1097(12)61787-2

48. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham Heart Study / S. R. Preis, J. M. Massaro, S. J. Robins et al. // Obesity - 2010. - 18(11). - Р. 2191-2198.

49. Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults / I. J. Neeland, A. T. Turer, C. R. Ayers et al. // JAMA. - 2012. - 308(11). - Р. 1150-1159. - Doi : 10.1001/2012.jama.11132.

50. Abdominal Obesity and the Metabolic Syndrome: Contribution to Global Cardiometabolic Risk / J. P. Desprйs, I. Lemieux, J. Bergeron, P. Pibarot, P. Mathieu, E. Larose, J. R.Cabau, O. F. Bertrand, P. Poirier // Arterioscler. Thromb. Vasc. Biol. - 2008. - 28. - Р. 1039-1049.

51. Insulin Status and Vascular Responses to Weight Loss in Obesity / S. J. Bigornia, M. G. Farb, S. Tiwari et al. // J. Am. Coll. Cardiol. - 2013. - 62(24). - Р. 2297-2305. - Doi : 10.1016/j.jacc.2013.07.078

52. Thomas, M. C. Assessment and management of hypertension in patients with type 2 diabetes / M. C. Thomas, R. Atkins // Intern. Med. J. - 2009. - 39(3). - Р. 143-149.

53. Apelin, diabetes, and obesity / I. Castan-Laurell, C. Dray, C. Attanй et al. // Endocrine. - 2011. - 40(1). - P. 1-9.

54. Structure-Activity Relationship Studies toward the Discovery of Selective Apelin Receptor Agonists / J. F. Margathe, X. Iturrioz, R. Alvear-Perez et al. // Journal of Medicinal Chemistry. - 2014. - 57(7). - P. 2908-2919.

55. Liquid chromatography/tandem mass spectrometry assay for the absolute quantification of the expected circulating apelin peptides in human plasma / C. Mesmin, M. Dubois, F. Becher et al. // Rapid. Commun. Mass Spectrom. - 2010. - 24(19). - P. 2875-2884.

56. Structural insight into G-protein coupled receptor binding by apelin / D. N. Langelaan, E. M. Bebbington, T. Reddy, J. K. Rainey // Biochemistry. - 2009. - 48. - P. 537-548.

57. Ontogeny of apelin and its receptor in the rodent gastrointestinal tract / G. Wang, R. Kundu, S. Han et al. // Regul. Pept. - 2009. - 158(1-3). - P. 32-39.

58. Apelin is necessary for the maintenance of insulin sensitivity / P. Yue, H. Jin, M. Aillaud-Manzanera et al. // Amer. J. Physiol. Endocrinol. Metab. - 2009. - 298. - P. 59-67.

59. Apelin is a novel islet peptide / C. Ringstroem, M. D. Nitert, H. Bennet et al. // Reg. Peptides. - 2010. - 162. - P. 44-51.

60. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity / M. Sawane, K. Kajiya, H. Kidoya et al. // Diabetes. - 2013. - 62(6). - P. 1970-1980.

61. Vascular effects of apelin in vivo in man / A. G. Japp, N. L. Cruden, D. A. Amer et al. // J. Am. Coll. Cardiol. - 2008. - 52. - P. 908-913.

62. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes / K. Rittig, U. Hildebrandt, C. Thamer et al. // J. Exper. and Clin. Endocrinol. and Diabetes. - 2011. - 119(6). - P. 358-361.

63. Barnes, G. Translational promise of the apeline - APJ system / G. Barnes, A. G. Japp, D. E. Newby // Heart. - 2010. - 96. - P. 1011-1016.

64. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis / H. J. Chun, Z. A. Ali, Y. Kojima et al. // J. Clin. Invest. - 2008. - 118(10). - Р. 3343-3354.

65. А Newly Identified Adipokine Up-Regulated by Insulin and Obesity / J. Boucher, B. Masri, D. le Daviaud, S. Gesta, C. Guigne', A. Mazzucotelli, I. Castan -Laurell, I. Tack, B. Knibiehler, C. Carpe'ne', Y. Audigier, J. Saulnier-Blache, P. Valet Apelin // Endocrinology. - 2005. - 146(4). - Р. 1764-1771.

66. Than, A. Apelin Attenuates Oxidative Stress in Human adipocytes / A. Than, X. Zhang, M. Khee-Shing Leow // Biol. Chem. - 2014. - 289. - P. 3763-3774.

67. Xu, S. Apelin and insulinresistance: another arrow for the quiver? / S. Xu, P. S. Tsao, P. Yue // J. Diabetes. - 2011. - 3(3). - Р. 225-231.

68. Identification and characterization of apelin peptides in bovine colostrum and milk by liquid chromatography-mass spectrometry / C. Mesmin, F. Fenaille, F. Becher et al. // J. Proteome Res. - 2011. - 10(11). - P. 5222-5231.

69. Sgourakis, N. G. Prediction of the coupling specificity of GPCRs to four families of G-proteins using hidden Markov models and artificial neural networks / N. G. Sgourakis, P. G. Bagos, S. J. Hamodrakas // Bioinformatics. - 2005. - 21(22). - P. 4101-4106.

70. Steinberg, G. R. AMPK in Health and Disease / G. R. Steinberg, B. E. Kemp // Physiol. Rev. - 2009. - 89(3). - P. 1025-1078.

71. Apelin alleviates diabetes-associated endoplasmic reticulum stress in the pancreas of akita mice / H. Chen, C. Zheng, X. Zhang et al. - Peptides. - 2011. - 32(8). - P. 1634-1639.

72. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice / C. Dray, C. Knauf, D. Daviaud et al. // Cell. Metab. - 2008. - 8. - P. 437-445.

73. Adipokines in inflammation and metabolic disease. / N. Ouchi, J. L. Parker, J. J. Lugus, K. Walsh // Nat. Rewiews. Immunology. - 2011. - 11. - P. 85-97.

74. Apelin protects myocardial injury induced by isoproterenol in rats / Y. X. Jia, C. S. Pan, J. Zhang et al. // Regul.Pept. - 2006. - 15(133(1-3)). - P. 147-154.

75. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation / N. J. Leeper, M. M. Tedesco, Y. Kojima et al. // Am. J. Physiol. Heart. Circ. Physiol. - 2009. - 296(5). - Р. 1329-1335.

76. Kleinz, M. J. Emerging roles of apelin in biology and medicine / M. J. Kleinz, A. P. Davenport // Pharmacol. Ther. - 2005. - 107(2). - P. 198-211.

77. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects / L. Li, G. Yang, Q. Li et al. // Exp. Clin. Endocrinol. Diabetes. - 2006. - 114. - P. 544-548.

78. Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms / P. Yue, H. Jin, S. Xu et al. // Endocrinology. - 2011. - 152(1). - P. 59-68.

79. Apelin inhibits insulin secretion in pancreatic в-cells by activation of PI3-kinase-phosphodiesterase 3B / L. Guo, Q. Li, W. Wang, Р. Yu et al. // Endocrine research. - 2009. - 34. - P. 142-154.

80. Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges / M. R. Seyyed, Kazemi-Bajestani, B. Vaibhav et al. // Cardiology Research and Practice. - 2012. - 2012. - P. 1-11.

81. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus / F. Soriguer, L. Garrido-Sanchez, S. G. Serrano et al. // Obesity Surgery. - 2009. - 19(11). - P. 1574-1580.

82. Central apelin controls glucose homeostasis via a nitric oxide-dependent pathway in mice / T. Duparc, A. Colom, P. D. Cani et al. // Antioxidants and Redox Signaling. - 2011. - 6(15). - P. 1477-1496.

83. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasisj / A. M. O'Carroll, S. J. Lolait, L. E. Harris, G. R. Рope // Endocrinol. - 219(1) - Р. R13-35. - Doi : 10.1530/JOE-13-0227

84. Low Plasma Apelin Levels in Newly Diagnosed Type 2 Diabetes Mellitus / G. Erdem, T. Dogru, I. Tasci et al. // Exp. Clin. Endocrinol. Diabetes. - 2008. - 116(5). - Р. 289-292.

85. Colosia, Ann D. Prevalence of Hypertension and Obesity in Patients with Type 2 Diabetes Mellitus in Observational Studies: A Systematic Literature Review / A. D. Colosia, R. Palencia, S. Khan // Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. - 2013. - 6 - Р. 327-338.

86. Rosen, E. D. What we talk about when we talk about fat / E. D. Rosen, B. M. Spiegelman // Cell. - 2014. - 156. - Р. 20-44. - Doi : 10.1016/j.cell.2013.12.012

87. High Prevalence of Glucose Intolerance and Diabetes in Patients with Coronary Artery Disease / S. Varol, V. Sansoy, O. Abacэ, M. Kalyoncuoglu // J. Am. Coll. Cardiol. - 2013. - 62(18_S2). - Р. C213-214. - Doi : 10.1016/j.jacc.2013.08.606

88. Masuo, Kazuko. Hypertension and Diabetes in Obesity / K. Masuo, M. L. Tuck, G. W. Lambert // International Journal of Hypertension. - 2011. -Р. 11-12, Doi : 10.4061/2011/695869

89. Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine / S. Ylд-Herttuala, T. T. Rissanen, I. Vajanto, J. Hartikainen // J. Am. Coll. Cardiol. - 2007. - 49(10). - Р. 1015-1026. - Doi : 10.1016/j.jacc.2006.09.053.

90. Gerhardt, H. VEGF and endothelial guidance in angiogenic sprouting / H. Gerhardt // Organogenesis. - 2008. - 4(4). - Р. 241-246.

91. Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGFb / W. Zheng, E. A. Seftor, C. J. Meininger et al. // Amer. J. Phisiol. Heart Circ. Phisiol. - 2001. - 280. - P. 909-917.

92. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin / A. Orecchia, P. M. Lacal, C. Schietroma et al. // J. Cell. Sci. - 2003. - 116. - Р. 3479-3489.

93. Vascular endothelial growth factor enchances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis / Y. Masuda, A. Shimizu, T. Mori et al. // Am. J. Pathol. - 2001. - 159. - P. 599-608.

94. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function / W. Lieb, R. Safa, E. J. Benjamin et al. // Eur. Heart J. - 2009. - 30. - P. 1121-1127.

95. Vascular protection: a novel nonangiogenic cardiovascular role for VEGF / I. Zachary, A. Mathur, S. Yla-Herttuala, J. Martin // Arterioscler. Thromb. Vasc. Biol. - 2000. - 20. - P. 1512-1520.

96. Tsutsumi, Y. Double face of VEGF / Y. Tsutsumi, D. W. Losordo // Circulation. - 2005. - 112. - P. 1248-1250.

97. Testa, U. Vascular endothelial growth factors in cardiovascular medicine / U. Testa, G. Pannitteri, G. L. Condorelli // J. Cardiovasc. Med. - 2008. - 9. - Р. 1190-1221.

98. Ferrara, N. Molecular and biological properties of VEGF / N. Ferrara // J. Mol. Med. - 1999. - 77. - P. 527-543.

99. Takahashi, H. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions / H. Takahashi, M. Shibuya // Clin. Sci. - 2005. - 109. - Р. 227-241.

100. Ferrara, N. The biology of VEGF and its receptors / N. Ferrara, H. P. Gerber, J. le Couter // Nat. Med. - 2003. - 9. - Р. 669-676.

101. Березин, A. E. Васкулярный эндотелиальный фактор роста 1 как предиктор неблагоприятных кардиоваскулярных событий у пациентов с гипертонической болезнью III стадии. Результаты одногодичного наблюдения. Часть I / A. E. Березин, O. A. Лисовая // Международный неврологический журнал. - 2014. - 1(63). - С. 61-67.

102. Hermann, D. M. Implications of vascular endothelial growth factor for post ischemic neurovascular remodeling / D. M. Hermann, A. Zechariah // J. Cereb. Blood Flow. Metab. - 2009. - 29. - Р. 1620-1643.

103. Trayhurn, P. Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity / P. Trayhurn // Annu. Rev. Nutr. - 2014. - 34. - Р. 207-236. - Doi : 10.1146/ annurev-nutr-071812-161156

104. Goossens, G. H. Adipose tissue oxygen tension: implications for chronic metabolic and inflammatory diseases / G. H. Goossens, E. E. Blaak // Curr. Opin. Clin. Nutr. Metab. Care. - 2012. - 15. - Р. 539-546. - Doi : 10.1097/MCO.0b013e328358fa87

105. Metabolic signatures of human adipose tissue hypoxia in obesity / L. Hodson, S. M. Humphreys, F. Karpe, K. N. Frayn // Diabetes. - 2013. - 62. - Р. 1417-1425. - Doi : 10.2337/ db12-1032

106. Goossens, G.H. Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen? / G. H. Goossens, E. E. Blaak // Front. Endocrinol. - 2015. - 6. - Р. 55.

107. Bluher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases / M. Bluher // Best Pract. Res. Clin. Endocrinol. Metab. - 2013. - 27. - Р. 163-177. - Doi : 10.1016/j. beem.2013.02.005

108. Ten nights of moderate hypoxia improves insulin sensitivity in obese humans / G. H. Goossens, C. Lecoultre et al. // Diabetes Care. - 2014. - 37. - Р. e155-156. - Doi : 10.2337/dc14-0097.

109. Ye, J. Adipose Tissue Vascularization: Its Role in Chronic Inflammation / J. Ye // Current diabetes reports. - 2011. - 11(3). - Р. 203-210. - Doi : 10.1007/s11892-011-0183-1

110. Takayoshi S. Adipose tissue inflammation and ectopic lipid accumulation / T Suganami, M. Tanaka, Y. Ogawa // Endocrine Journal. - 2012. - 10(59). - Р. 849-857.

111. Adipocyte mitochondrial function is reduced in human obesity independent of fat cell size / X. Yin, I. R. Lanza, J. M. Swain, M. G. Sarr, K. S. Nair, M. D. Jensen // J. Clin. Endocrinol. Metab. - 2014. - 99. - Р. е209-216. - Doi : 10.1210/jc.2013-3042

112. Adipose Tissue Overexpression of Vascular Endothelial Growth Factor Protects Against Diet-Induced Obesity and Insulin Resistance / I. Elias, S. Franckhauser, T. Ferrй, L. Vilа, S. Tafuro, S. Muсoz, F. Bosch // Diabetes. - 2012. - 61(7). - Р. 1801-1813 - Doi : 10.2337/db11-0832

113. Vascular endothelial growth factor Bcontrols endothelial fatty acid uptake / C. E. Hagberg, A. Falkevall, X. Wang, et al. // Nature. - 2010. - 464. - Р. 917-921.

114. Vascular endothelial growth factor-B as a therapeutic target to prevent ectopic fat deposition / H., Tetsuya, S. Nomura, F. Kazuhiro, A. Ogawa, S. Wataru / J. Diabetes Invest. - 2013. - 4(6). - Р. 525-527.

115. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes / C. E. Hagberg, A. Mehlem, A. Falkevall et al. // Nature. - 2012. - 490. - Р. 426-430.

116. Obesity-associated insulinresistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels / F. J. Tinahon, L. Coin-Araguez, M. D. Mayas et al. // BMC Physiol. - 2012. - 4(12). - Р. 265-269.

117. Lu, X. Resistance to obesity by repression of VEGF gene expression through induction of brown-like adipocyte differentiation / X. Lu, Y. Ji, L. Zhang et al. // Endocrinology. - 2012. - 153. - Р. 3123-3132.

118. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle / T. Kubota, N. Kubota, H. Kumagai et al. // Cell Metab. - 2011. - 13. - Р. 294-307.

119. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin / N. Garcнa de la Torre, M. A. Rubio, E. Bordiъ, L. Cabrerizo, E. Aparicio, C. Hernбndez, A. Sбnchez-Pernaute, L. Dнez-Valladares, A. J. Torres, M. Puente, A. L. Charro // J. Clin. Endocrinol. Metab. - 2008. - 93(11). - Р. 4276-4281.

120. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance / H. Wada, N. Satoh, S. Kitaoka, K. Ono, T. Morimoto, T. Kawamura, T. Nakano, M. Fujita, T. Kita, A. Shimatsu, K. Hasegawa // Atherosclerosis. - 2010. - 208(2). - Р. 512-517.

121. Evidence for a Relationship between VEGF and BMI Independent of Insulin Sensitivity by Glucose Clamp Procedure in a Homogenous Group Healthy Young Men / M. Loebig, J. Klement, A. Schmoller, S. Betz, N. Heuck, U. Schweiger, K. M. Oltmanns // PLoS ONE. - 2010. - 5(9). - Р. e12610. - Doi : 10.1371/journal.pone.0012610

122. Angiogenic factors are elevated in overweight and obese individuals / J. V. Silha, M. Krsek, P. Sucharda, L. J. Murphy // Int. J. Obes. (Lond). - 2005. - 29(11). - Р. 1308-1314.

123. Serum VEGF - as a prognostic factor of atherosclerosis / K. Kimura, T. Hashiguchi, T. Deguchi, S. Horinouchi, T. Uto, H. Oku, S. Setoyama, I. Maruyama, M. Osame, K. Arimura // Atherosclerosis. - 2007. - 194(1). - Р. 182-188.

124. Glucose turnover and intima media thickness of internal carotid artery in type 2 diabetes offspring / C. Anderwald, G. Pfeiler, P. Nowotny, M. Anderwald-Stadler, M. Krebs, M. G. Bischof, M. Kozakova, A. Luger, G. Pacini, M. Roden, W. Waldhдusl // Eur. J. Clin. Invest. - 2008. - 38(4). - Р. 227-237.

125. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals / H. S. Randeva, K. C. Lewandowski, J. Komorowski, R. D. Murray, C. J. O'Callaghan, E. W. Hillhouse, H. Stepien, S. M. Shalet // Circulation. - 2004. - 109(20). - Р. 2405-2410.

126. Apelin is a crucial factor for hypoxia-induced retinal angiogenesis / A. Kasai, Y. Ishimaru, T. Kinjo, T. Satooka, N. Matsumoto, Y. Yoshioka et al. // Arterioscler. Thromb. Vasc. Biol. - 2010. - 30. - Р. 2182-2187.

127. Kidoya, H. Biology of the apelin-APJ axis in vascular formation / H. Kidoya, N. Takakura // J. Biochem. - 2012. - 152(2). - Р. 125-131.

128. Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways / R. R. Cui, D. A. Mao, L. Yi, C. Wang, X. X. Zhang, H. Xie et al. // Amino Acids. - 2010. - 39. - Р. 1193-1200.

129. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. / M. Eyries, G. Siegfried, M. Ciumas, K. Montagne, M. Agrapart, F. Lebrin et al. // Circ. Res. - 2008. - 103. - Р. 432-440.

130. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction / A. M. Kuklinska, B. Sobkowicz, R. Sawicki et al. // Heart and Vessels. - 2010. - 25(5). - Р. 363-367.

131. Li, L. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction / L. Li, H. Zeng, J. X. Chen // Amer. J. of Physiology Heart. Circ. Physiol. - 2012. - 303(5). - Р. 605-618.

132. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study / D. Levy, R. J. Garrison, D. D. Savage et al. // New Engl. J. Med. - 1990. - 322. - P. 1561-1566.

133. Molecular imaging of the cardiac extracellular matrix / H. J. de Haas, E. Arbustini, V. Fuster et al. // Circ. Res. - 2014. - 114(5). - Р. 903-915.

134. Ouzounian, M. Diastolic heart failure: mechanisms and controversies / M. Ouzounian, D. S. Lee, P. P. Liu // Nat. Clin. Pract. Cardiovasc. Med. - 2008. - 5. - Р. 375-386.

135. Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction: insights from the REVE-2 study / R. Eschalier, M. Fertin, R. Fay et al. // Circ. Heart Fail. - 2013. - 6(6). - Р. 1199-1205.

136. Кількісна ехокардіографічна оцінка порожнин серця: проект рекомендацій робочої групи з функціональної діагностики Асоціації кардіологів України та Всеукраїнської громадської організації «Асоціація фахівців з ехокардіографії» / В. М. Коваленко, Ю. А. Іванів, М. М. Долженко, С. І. Деяк, С. В. Поташев, Н. М. Носенко // Новости медицины и фармации (Кардиология). - 2011. - 39 с.

137. Paulus, W. J. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation / W. J. Paulus, C. Tschцpe // J. Am. Coll. Cardiol. - 2013. - 62(4). - Р. 263-271.

138. Vascular effects of apelin in vivo in man / A. G. Japp, N. L. Cruden, D. A. Amer, et al. // J. Am. Coll. Cardiol. - 2008. - 52. - P. 908-913.

139. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure / A. Y. Sheikh, H. J. Chun, A. J. Glassford et al. // Amer. J. Physiol. Heart Circ. Physiol. - 2008. - 294. - P. 88-98.

140. The apelin-APJ pathway exists in cardiomyogenic cells derived from mesenchymal stem cells in vitro and in vivo / L. R. Gao, N. K. Zhang, J. Bai et al. // Cell Transplantation. - 2010. - 19(8). - Р. 949-958.

141. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction / M. Agnieszka, M. Kuklinska, B. Sobkowicz, R. Sawicki, W. J. Musial, E. Waszkiewicz, S. Bolinska, J. Maіyszko // Heart and Vessels. - 2010. - 25(5). - Р. 363-367.

142. Direct effects of apelin on cardiomyocyte contractility and electrophysiology / K. Farkasfalvi, M. A. Stagg, S. R. Coppen et al. // Biochem. And Biophys. Res. Commun. - 2007. - 357(4). - Р. 889-895.

143. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man / S. L. Pitkin, J. J. Maguire, R. E. Kuc, A. P. Davenport // British. J. of Pharmacol. - 2010. - 160(7). - Р. 1785-1795.

144. Sasso, F. C. Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats / F. C. Sasso, O. Carbonara, E. Persico // Metabolism. - 2003 - 52. - Р. 675-678.

145. Marfella, R. Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes / R. Marfella, K. Esposito, F. Nappo // Diabetes. - 2004 - 53. - Р. 2383-2391.

146. Increased Vascular Endothelial Growth Factor Expression But Impaired Vascular Endothelial Growth Factor Receptor Signaling in the Myocardium of Type 2 Diabetic Patients With Chronic Coronary Heart Disease / F. Sasso, D. Torella, O. Carbonara et al. // J. Am. Coll. Cardiol. - 2005. - 46(5). - Р. 827-834. - Doi : 10.1016/j.jacc.2005.06.007

147. Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity / R. Eschalier, P. Rossignol, A. Kearney-Schwartz et al. // Hypertension. - 2014. - 63(4). - Р. 740-746.

148. van Linthout, S. Crosstalk between fibroblasts and inflammatory cells / S. van Linthout, K. Miteva, C. Tschцpe // Cardiovasc. Res. - 2014. - 102(2). - Р. 258-269.

149. Mathis, S. Immunometabolism: an emerging frontier / S. Mathis, S. E. Shoelson // Nat. Rev. Immunol. - 2011. - 11. - P. 81

150. Kubin, T. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling / T. Kubin, J. Pling, S. Kostin // Cell Stem. Cell. - 2011. - 9. - P. 420-432.

151. Signaling network of Oncostatin M pathway / G. Dey, A. Radhakrishnan, N. Syed, J. K. Thomas, A. Nadig, K. Srikumar, P. P. Mathur, A. Pandey, S. K. Lin, R. Raju, T. S. Keshava-Prasad // Journal of Cell Communication and Signaling. - 2013. - 7(2). - Р. 103-108.

152. Net Path: a public resource of curated signal transduction pathways / K. Kandasamy, S. S. Mohan, R. Raju, S. Keerthikumar, G. S. Kumar, A. K. Venugopal, D. Telikicherla et al. // Genome Biol. - 2010. - 11. - Р. R3. - Doi : 10.1186/gb-2010-11-1-r3

153. CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes / K. Migita, A. Komori, T. Torigoshi, Y. Maeda, Y. Izumi, Y. Jiuchi, T. Miyashita, M. Nakamura, S. Motokawa, H. Ishibashi // Arthritis. Res. Ther. - 2011. - 13. - Р. R72. - Doi : 10.1186/ar3333

154. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines / S. L. Fossey, M. D. Bear, W. C. Kisseberth, M. Pennell, C. A. London // BMC Cancer. - 2011. - 11. - Р. 125. - Doi : 10.1186/1471-2407-11-125

155. Enhancement of placenta growth factor expression by oncostatin M in human rheumatoid arthritis synovial fibroblasts / H. J. Tu, T. H. Lin, Y. C. Chiu, C. H. Tang, R. S. Yang, W. M. Fu // J. Cell Physiol. - 2012. - 9. - Р. 325-329.

156. Oncostatin M is a novel inhibitor of TGF-beta1-induced matricellular protein expression / R. Sarkozi, C. Hauser, S. J. Noppert, A. Kronbichler, M. Pirklbauer, V. M. Haller, J. Grillari, R. Grillari-Voglauer, G. Mayer, H. Schramek // Am. J. Physiol. Renal. Physiol. - 2011. - 301. - Р. 1014-1025. - Doi : 10.1152/ajprenal.00123.2011

157. OSM Enhances Angiogenesis and Improves Cardiac Function after Myocardial Infarction / X. Zhang, D. Zhu, L. Wei et al. // Bio. Med. Research International. - 2015. - 2(15). - 10 p. - Doi : 10.1155/2015/317905

158. Opposing roles of STAT-1 and STAT-3 in regulating vascular endothelial growth factor expression in vascular smooth muscle cells / A. Albasanz-Puig, J. Murray, M. Namekata, E. S. Wijelath // Biochem. Biophys. Res. Commun. - 2012. - 428(1). - Р. 179-184. - Doi : 10.1016/j.bbrc.2012.10.037

159. The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo / K. Rychli, C. Kaun, P. J. Hohensinner et al. // Journal of Thrombosis and Haemostasis. - 2010. - 3(8). - Р. 596-604.

160. Richard, A. J. The role of JAK-STAT signaling in adipose tissue function / A. J. Richard, J. M. Stephens // Biochim. Biophys. Acta. - 2014. - 1842. - P. 431-439.

161. Harmancey, R. Adaptation and maladaptation of the heart in obesity / R. Harmancey, C. R. Wilson, H. Taegtmeyer // Hypertension. - 2008. - 52(2). - P. 181-187.

162. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition / I. Hameed, S. R. Masoodi, S. A. Mir, M. Nabi, K. Ghazanfar, B. A. Ganai // World Journal of Diabetes. - 2015. - 6(4). - Р. 598-612.

163. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission / T. C. Wong, K. M. Piehler, I. A. Kang et al. // Eur. Heart J. - 2014. - 35(10). - Р. 657-664.

164. Therapeutic targets in heart failure: refocusing on the myocardial interstitium / E. B. Schelbert, G. C. Fonarow, R. O. Bonow et al. // J. Am. Coll. Cardiol. - 2014. - Р. S0735-1097(14)01397-7

165. Jarolim, P. Overview of cardiac markers in heart disease / P. Jarolim // Clin. Lab. Med. - 2014. - 34(1). - Р. 1-14.

166. Ezzati M. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration / M. Ezzati // Lancet Diabetes Endocrinol. - 2014. - 2. - Р. 634-647.

167. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 / R. Lozano, M. Naghavi, K. Foreman et al. // Lancet. - 2012. - 380. - Р. 2095-2128.

168. Long-termeffects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a reportfrom theDPP Outcomes Study / Diabetes Prevention Program Outcomes Study Research Group, T. J. Orchard, M. Temprosa, E. Barrett-Connor, S. E. Foyler et al. // Diabet Med. - 2013. - 30. - Р. 46-55.

169. Ferrannini E. The Target of Metformin in Type 2 Diabetes / E. Ferrannini // N. Engl. J. Med. - 2014. - 371(16). - P. 1547-1548.

170. Паньків, В. І. Цукровий діабет 2-го типу: як уникнути помилок і підвищити ефективність лікування / В. І. Паньків // Международный эндокринологический журнал. - 2013. - 4(52). - С. 4-8.

171. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) / S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, D. R. Matthews // Diabetes Care. - 2012. - 35(6). - Р. 1364-1379. - Doi : 10.2337/dc12-0413

172. Grant, J. S. An Overview of Metformin and Implications in the Workplace / J. S. Grant, L. A. Steadman // Workplace Health Saf. - 2015. - 63. - Р. 424-426.

173. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes / S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, D. R. Matthews // Diabetes Care. - 2015. - 38(1). - Р. 140-149. - Doi : 10.2337/dc14-2441

174. Metformin Pharmacogenomics: Current Status and Future Directions / A. C. Pawlyk, K. M. Giacomini, C. McKeon, A. R. Shuldiner, J. C. Florez // Diabetes. - 2014. - 63(8). - Р. 2590-2599. - Doi : 10.2337/db13-1367

175. Радченко, А. Н. Применеие метформина у больных сахарным диабетом: взгляд кардиолога / А. Н. Радченко // Артериальная гипертензия. - 2011. - 3. - С. 50-63.

176. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, MAGIC Investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes / K. Zhou, C. Bellenguez, C. C. Spencer et al. // Nat. Genet. - 2011. - 43. - Р. 117-120.

177. Holman, R. R. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes / R. R. Holman, H. Sourij, R. M. Califf // Lancet. - 2014. - 383. - Р. 2008-2017.

178. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials / C. Lamanna, M. Monami, N. Marchionni, E. Mannucci // Diabetes, Obesity and Metabolism - 2011. - 13. - Р. 221-228.

179. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program / J. B. Sussman, D. M. Kent, J. P. Nelson, R. A. Hayward // BMJ. - 2015. - 350. - Р. 454. - Doi : 10.1136/bmj.h454

180. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies:apost-hoc analysis of the BIGPRO 1 trial / A. Fontbonne, I. Diouf, M. Baccara-Dinet, E. Eschwege, M. A. Charles // Diabetes Metab. - 2009. - 35. - Р. 385-391.

181. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP / R. A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet, M. J. Birnbaum // Nature. - 2013. - 494. - Р. 256-260.

182. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state / M. Foretz, S. Hйbrard, J. Leclerc et al. // J. Clin. Invest. - 2010. - 120. - Р. 2355-2369.

183. Zolk, O. Disposition of metformin: variability due to polymorphisms of organic cation transporters / O. Zolk // Ann. Med. - 2012. - 44. - Р. 119-129.

184. Metformin pathways: pharmacokinetics and pharmacodynamics / L. Gong, S. Goswami, K. M. Giacomini, R. B. Altman, T. E. Klein // Pharmacogenet Genomics. - 2012. - 22. - Р. 820-827.

185. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study / Diabetes Prevention Program Research Group, W. C. Knowler, S. E. Fowler, R. F. Hamman, C. A. Christophi et al. // Lancet. - 2009. - 374. - Р. 1677-1686.

186. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study / W. C. Knowler, W. C. Fowler, R. F. Hamman et al. ; Diabetes Prevention Program Research Group // Diabetes Care. - 2012. - 35. - Р. 731-737.

187. Effects of metformin on the regulation of free fatty acids in insulin resistance: a double-blind, placebo-controlled study / M. Castro Cabezas, J. P. van Wijk, J. W. Elte, B. Klop // J. Nutr. Metab. - 2012. - 9(3). - Р. 462-463.

188. A clinical trial to maintain glycemic control in youth with type 2 diabetes / P. Zeitler, K. Hirst, L. Pyle et al. // N. Engl. J. Med. - 2012. - 366. - Р. 2247-2256.

189. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1 / N. Ouslimani, M. Mahrouf, J. Peynet et al. // Metabolism. - 2007. - 56(3). - P. 308-313.

190. Rena, G. Molecular action and pharmacogenetics of metformin: current understanding of an old drug / G. Rena, E. R. Pearson, K. Sakamoto // Diabetes Management. - 2012. - 2. - Р. 439-452.

191. Shah, D. D. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes / D. D. Shah, G. C. Fonarow, T. B. Horwich // J. Cardiac Failure - 2010. - 16. - Р. 200-206.

192. Fay, W. P. Vascular functions of the plasminogen activation system / W. P. Fay, N. Garg, M. Sunkar // Arterioscler. Thromb. Vasc. Biol. - 2007. - 27(6). - P. 1231-1237.

193. Metformin restores the penile expression of nitric oxide synthase in high fat-fed obese rats / Y. W. Kim, S. Y. Park, J. Y. Kim, J. Y. Huh // J. Androl. - 2007. - 26(3). - P. 34-38.

194. Cardiovascular safety of anti-diabetic drugs / R. Kumar, D. M. Kerins, T. Walther // European Heart Journal. Cardiovascular Pharmacotherapy. - 2015. - Р. 202-208. - Doi : 10.1093/ehjcvp/pvv035

195. Metformin inhibits proinflammatory responses and nuclear factor-(Nf-kb) in human vascular wall cells / K. Isoda, J. L. Young, A. Zirlik et al // Arterioscler. Thromb. Vasc. Biol. - 2006. - 26(3). - P. 611-617.

196. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial / J. de Jager, A. Kooy, C. Schalkwijk, J. van der Kolk, P. Lehert, D. Bets, M. G. Wulffelй, A. J. Donker, C. D. Stehouwer // J. Intern. Med. - 2014. - 275. - Р. 59-70.

197. Kamenova, P. Metformin Reduces Cardiometabolic Risk Factors in People at High Risk for Development of Type 2 Diabetes and Cardiovascular Disease / P. Kamenova, I. Atanasova, G. Kirilov // J. Diabetes Metab. - 2014. - 5. - Р. 470.

198. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart / S. Sen, B. K. Kundu, H. C. Wu, S. S. Hashmi, P. Guthrie, L. W. Locke, R. J. Roy, G. P. Matherne, S. S. Berr, M. Terwelp et al. // J. Am. Heart Assoc. - 2013. - 2(3). - Р. 796.

199. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis / B. Hemmingsen, J. B. Schroll, J. Wetterslev, C. Gluud, A. Vaag, D. P. Sonne, L. H. Lundstrоm, T. Almdal // CMAJ Open. - 2014. - 2. - Р. 162-175.

200. Хрисанфова, Е. Н. Антропология : учеб. / Е. Н. Хрисанфова, И. В. Перевозчиков. - М. : Изд-во МГУ, 1991. - 319 с.

201. Уніфікований клінічний протокол медичної допомоги «Ішемічна хвороба серця» МОЗ України. - 2011. - 41 с.

202. Наказ МОЗ України № 1118 від 21. 12. 2012 «Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при цукровому діабеті 2 типу». - https://www.moz.gov.ua/ua/portal/dn_20121221_1118.html.

203. Reappraisal of European guidelines on hypertension management : a European Society of Hypertension Task Force document / G. Mancia, S. Laurent, E. Agabiti-Rosei et al. // J. Hypertension. - 2009. - 27. - P. 2121-2158.

204. Артеріальна гіпертензія. Оновлена та адаптована клінічна настанова, заснована на доказах (2012 рік) / Робоча група з артеріальної гіпертензії Української асоціації кардіологів // Артеріальна гіпертензія. - 2012. - 1(21). - С. 96-152.

205. Рекомендації асоціації кардіологів України з діагностики, лікування та профілактики хронічної серцевої недостатності у дорослих / Л. Г. Воронкова, К. М. Амосова та ін. - К., 2010. - 48 с.

206. Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure / S. A. Hunt, W. T. Abraham, M. H. Chin et al. // Circulation. - 2005. - 112. - P. 154-235.

207. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) / L. Rydйn et al. // Eur. Heart. J. - 2007. - 28. - P. 88-136.

208. Obesity: preventing and managing the global epidemic: report of a WHO consultation / WHO. ? Geneva : WHO, 2000. - 894. - 253 p.

209. Du Bois, D. A formula to estimate the approximate surface area if height and weight be known / D. Du Bois, E. Du Bois // Arch. Intern. Med. - 1916. - 17. - P. 863-871.

210. Alberti, K. G. The metabolic syndrome - a new worldwide definition / K. G. Alberti, P. Zimmet, J. Shaw // Lancet. - 2005. - 366. - P. 1059-1062.

211. Waist Circumference and Waist-Hip Ratio: report of a WHO Expert Consultation / WHO. - Geneva : WHO, 2008. - 39 p.

212. Lindstrцm, J. The diabetes risk score: a practical tool to predict type 2 diabetes risk / J. Lindstrцm, J. Tuomilehto // Diabetes Care. - 2003. - 26. - P. 725-371.

213. Identifying adults at high risk for diabetes and cardiovascular disease using hemoglobin A1c / R. T. Ackerman et al. // Am. J. Prev. Med. - 2011. - 40(1). - Р. 11-17.

214. Diagnosing insulin resistance in the general population / K. A. McAuley et al. // Diabetes Care. - 2001. - 24. - P. 460-464.

215. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man / D. R. Matthews, J. P. Hosker, A. S. Rudenski et al. // Diabetologia. - 1985. - 28. - P. 412-419.

216. Insulin Sensitivity and Insulin Secretion Determined by Homeostasis Model Assessment (HOMA) and Risk of Diabetes in a Multiethnic Cohort of Women: The Women's Health Initiative Observational Study / Y. Song, J. E. Manson, L. Tinker et al. // Diabetes Care. - 2007. - 30(7). - Р. 1747-1752.

217. Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications / S. S. Martin, M. J. Blaha, M. B. Elshazly et al. // J. Am. Coll. Cardiol. - 2013. - 62(8). - Р. 732-739.

218. Лутай, М. І. Дисліпопротеїдемії: клінічне значення та класифікації / М. І. Лутай // Нова медицина. - 2003. - 4(9). - С.16-21.

219. Ковальова, О. М. Діагностика ендотеліальної функції - оцінка вазоактивного пулу оксиду азота: метод. рекомендації / О. М. Ковальова, Г. В. Демиденко, Т. В. Горбач. - Київ. - 2007. - 19 с.

220. American Society of Echocardiography recommendations foruse of echocardiography in clinical trials / J. S. Gottdiener, J. Bednarz, R. Devereux et al. // J. Am. Soc. Echocardiogr. - 2004. - 17. - P. 1086-1119.

221. Recommendations for chamber quanti?cation / R. M. Lang, M. Bierig, R. B. Devereux, F. A. Flachskampf, E. Foster, P. A. Pellikka, M. H. Picard, M. J. Roman, J. Seward, J. Shanewise, S. Solomon, K. T. Spencer, M. St. J. Sutton, W. Stewart // Eur. J. Echocardiography. - 2006. - 7. - Р. 79-108.

222. Du Bois, D. A formula to estimate the approximate surface area if height and weight be known / D. Du Bois, E. Du Bois // Arch. Intern. Med. - 1916. - 17. - P. 863-871.

223. Assessment of left ventricular function by the midwall fractional shortening/end-systolicstress relation in human hypertension / G. de Simone, R. B. Devereux, M. J. Roman, A. Ganau, P. S. Saba, M. H. Alderman et al. // J. Am. Coll. Cardiol. - 1994. - 23. - Р. 1444-1451.

224. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension / G. de Simone, R. B. Devereux, M. J. Koren, G. A. Mensah, P. N. Casale, J. H. Laragh // Circulation. - 1996. - 93. - Р. 259-265.

225. Left ventricular myocardial remodeling and contractile state in chronic aortic regurgitation / K. Tanguchi, T. Kawamoto, S. Kuki еt al. // Clin. Cardiol. - 2000. - 23. - P. 608-614.

226. Recommendations for chamber quantification: a report from the American society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with European Association of Echocardiography, a branch of the European Society of Cardiology / R. M. Lang, M. Bierig, R. B. Devereux et al. // J. Am. Soc. Echocardiogr. - 2005. - 18. - P. 1440-1463.

227. Left ventricular mass: allometric scaling, normative values, effect of obesity and prognostic performance / J. A. Chirinos, P. Segers, M. L. De Buyzere, R. A. Kronmal, M. W. Raja, D. De Bacquer et al. // Hypertension. - 2010. - 56. - Р. 91-98.

228. LV mass assessed by echocardiography and CMR, cardiovascular outcomes and medical practice / A. C. Armstrong, S. Gidding, O. Gjesdal, C. Wu, D. A. Bluemke, J. A. Lima // JACCCardiovasc. Imaging. - 2012. - 5. - Р. 837-848.

229. Cross-sectional multiplane transesophageal echocardiographic measurements: comparisonwith standard transthoracic values obtained in the samesetting / P. C. Colombo, A. Municino, A. Brofferio, L. Kholdarova, M. Nanna, A. Ilercil // Echocardiography. - 2002. - 19. - Р. 383-390.

230. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension / A. Ganau, R. B. Devereux, M. J. Roman et al. // J. Am. Coll. Cardiol. - 1992. - 19. - Р. 1550-1558.

231. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients / M. L. Muiesan, M. Salvetti, C. Monteduro, B. Bonzi, A. Paini, S. Viola et al. // Hypertension. - 2004. - 43. - Р. 731-738.

232. Piya, M. K. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin / M. K. Piya, P. G. McTernan, S. Kumar // J. of Endocrinology. - 2013. - 216. - Р. 1-15.

233. Julius, S. Overweight and hypertension: a 2-way street? / S. Julius, M. Valentini, P. Palatini // Hypertension. - 2000. - 35. - Р. 807-813.

234. Interleukin-6 enchances glucose-stimulated insulin secretion from pancreatic в -cells: potential involvement of the PLC-IP3-dependent pathway / T. Suzuki, J. Imai, T. Yamada, Y. Ishigaki, K. Kaneko, K. Uno, Y. Hasegawa // Diabetes. - 2011. - 60. - Р. 537-547.

235. Ferrannini, E. Insulin and Blood Pressure: Connected on a Circumference? / E. Ferrannini // Hypertension. - 2005. - 45. - Р. 347-348.

236. Impaired fasting glucose, blood pressure and cardiovascular disease mortality / P. Henry, F. Thomas, A. Benetos et al. // Hypertension. - 2002. - 40. - P. 458-463.

237. HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes / A. J. Glassford, P. Yue, A. Y. Sheikh et al. // Am. J. Physiol. Endocrinol. Metab. - 2007. - 293(6). - Р. 1590-1596.

238. Apelin stimulates glucose uptake but not lipolysis in human adipose tissue ex vivo / C. Attane, D. Daviaud, C. Dray et al. // J. Mol. Endocrinol. - 2011. - 46(1). - Р. 21-28.

239. General and abdominal adiposity and risk of death in Europe / T. Pischon, H. Boeing, K. Hoffmann, M. Bergmann, M. B. Schulze, K. Overvad, Y. T. van der Schouw, E. Spencer, K. G. Moons, A. Tjоnneland // New England Journal of Medicine. - 2008. - 359. - P. 2105-2120.

240. Endothelial dysfunction as a target for prevention of cardiovascular disease / D. Versari, E. Daghini, A. Virdis, L. Ghiadoni, S. Taddei // Diabetes Care. - 2009. - 32. - P. S314-321.

241. Angiogenesis Associated With Visceral and Subcutaneous Adipose Tissue in Severe Human Obesity / S. Ledoux, I. Queguiner, S. Msika et al. // Diabetes. - 2008. - 57(12). - Р. 3247-3257.

242. Gaasch W. H. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry / W. H. Gaasch, M. R. Zile // J. Am. Coll. Cardiol. - 2011. - Vol. 58 (17). - P. 1733-1740.

243. New ADA/EASD Concensus recommends metformin at diagnosis of type 2 diabetes / Diabetes Care. - 2006. - 29(8). - P.1963 - 1972.

244. Effects of the nitric oxide donors, sodium nitroprusside, on resting leg glucose uptake in patients with type 2 diabetes / D. C. Henstridge, B. A. Kingwell, M. F. Formoza, et al. // Diabetologia. - 2005. - 48. - P. 2602-2608.

245. Laaksonen D.F Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definition of the metabolic syndrome in a prospective cohort stady. / D. F. Laaksonen, H. M. Laaka, L. K. Niskanen et al // Am. J. Epidemiol. -2002. - 156. - P.1070-1077.

246. Kurukulasuriya R. Selective decreased in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes / R. Kurukulasuriya, M. Banerij, R. Chaiken, H. Lebovitz // Diabetes. - 1999. - 48. - P.A315.

247. Daskalopoulou S.S. Prevention and treatment of the metabolic syndrome / S. S. Daskalopoulou, D. P. Mikhailidis, M. Elisaf // Angiology. - 2004. -Vol.55(6). -P.3145-3152.

248. Mannucci E. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects / E. Mannucci, A. Ognibene, F.Cremasco et al. // Diabetes Care. - 2001. - 24(3). -P.489-494.

249. Kirpichnikov D. Metformin. An Update / D. Kirpichnikov, S. I. McFarlane, J. R. Sowers // Ann. Intern. Med. - 2002. - 137. -P. 25-33.

250. Hawley S.A. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism / S. A. Hawley, A. E. Gadalla, G. S. Olsen, D. G. Hardie // Diabetes. - 2002. - 51. - P.2420-2425.

251. Lee W. J. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase / W. J. Lee, I. K. Lee, H. S. Kim et al. // Arterioscler. Thromb. Vasc. Biol. - 2005. - 25. - P.2488-2494.

252. Antidiabetes drug metformin is a donor of nitric oxide: ESR measurement of efficiency / V.F. Serezhenkov, I. S. Kuznetsov, T. I. Romantsova, M. I. Kuznetsova el.al. // Biophysics/ - 2011. - 56(6). - Р. 1088-1095.

253. Matsumoto T. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes / T. Matsumoto, E. Noguchi, K. Ishida et al. // Am. J. Physiol. Heart. Circ. Physiol. - 2008. - 295(3). - P.1165 - 1176.

254. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study / S. Jadhav, W. Ferrell, I. A. Greer et al. // J.Am.Coll.Cardiol. - 2006. - 48 (5). - P.956-963.

255. Rega G. Inflammatory Cytokines Interleukin-6 and Oncostatin M Induce Plasminogen Activator Inhibitor-1 in Human Adipose Tissue / G. Rega, C. Kaun, T.W. Weiss // Circulation. - 2005. - Vol.111. - P.1938-1945.

256. Mamputu J.C. Antiatherogenic properties of metformin: the experimental evidence / J. C. Mamputu, N. F. Wiernsperger, G. A. Renier // Diabetes Metab. - 2003. - 29 (6). - P.71-76.

257. Scarpello J.H. Improving survival with metformin: the evidence base today. / J. H. Scarpello // Diabetes Metab. - 2003. -Vol. 29(6). -P.36-43.

258. Tzou W.S. Increased subclinical atherosclerosis in young adults with metabolic syndrome: The Bogalusa Heart Study / W.S. Tzou, P.S. Douglas, S.R. Srinivasan et al. // J. Am. Coll. Cardiol. - 2005. - Vol. 46 (3). - P.457- 463.

259. Grand P.J. Beneficial effects of metformin on hemostasis and vascular function in max / P.J. Grand //Diabetes Metab. - 2003. -Vol. 29(6). - P.45-52.

260. Hong Y. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality - results of prospective analysis for the Atherosclerosis Risk in Communities study / Y. Hong, X. Jin, J. Mo // J.Intern.Med. - 2007. -Vol. 262(1). - P.113-123.

261. Rega G. Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo / G. Rega, C. Kaun, S. Demyanets [et al.] // Arterioscler.Thromb.Vasc.Biol. - 2007. - Vol. 27(7). - P. 1587 - 1595.

262. Rexrode K.M. Relationship of total and abdominal adiposity with CRP and IL-6 in women / K.M. Rexrode, A. Pradhan, J.E. Manson [et al.] // Ann. Epidemiol. - 2003. - Vol.13. - P.674-682.

263. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34) / UK Prospective Diabetes Stydy (UKPDS) Group // Lancet. - 1998. - 352. - P. 854-865.

264. Davis B.J. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase / B.J.Davis, Z.Xie, B.Viollet, M.H.Zou // Diabetes. - 2006. - Vol.55 (2). -P.496-450.

265. De Aquiar L.G. Metformin improves endothelial vascular reactivity in first-degree relatives of type diabetic patient with metabolic syndrome and normal glucose tolerance / L.G De Aquiar., L.R.Bahia N., Villela // Diabetes Care. - 2006. - Vol. 29 (5). -P.1083-1089.

266. Гублер, Е. В. Вычислительные методы анализа и распознавания патологических процессов / Е. В. Гублер // Л.: Медицина, 1978. - 274. с.

267. Минцер О.П. Кибернетическое прогнозирование в пульмонологии / О. П. Минцер, В. Н. Молотков // М.: Медицина. - 1983. - с.54.

268. Сиренко Ю. Н. Стандарты медицинской помощи при сахарном диабете (американская ассоциация сахарного диабета, 2015) / Ю. Н. Сиренко // Артериальная гипертензия. - 2015. - № 4 (42). - С. 95-99.

269. Diabetes mellitus and vascular endothelial dysfunction: current perspectives / D. Tousoulis, A. M. Kampoli, C. Stefanadis et al. // Curr. Vasc. Pharmacol. - 2012. - 10. - С. 19-32.

270. Маньковский Б. Н. Новое руководство по лечению сахарного диабета 2 типа - что изменилось, в чем значение для клинической практики? / Б. Н. Маньковский // Диабет. Ожирение. Метаболический синдром. - 2012. - № 1. - С. 31-36.

271. Diabetes Mellitus-Associated Vascular Impairment: Novel Circulating Biomarkers and Therapeutic Approaches / D. Tousoulis, N. Papageorgiou, E. Androulakis et al. // J. Am. Coll. Cardiol. - 2013. - 62(8). - С. 667-676.

272. Свищенко Е. П. Коморбидность артериальной гипертензии и сахарного диабета 2 типа / Е. П. Свищенко, Б. Н. Маньковский, Д. Д. Иванов // Здоровье Украины. - 2013.- № 1 (302). - С. 14-15.

273. Diabetes and cardiovascular disease in older adults: current status and future directions / J. B. Halter, N. Musi, H. F. McFarland, J. P. Crandall, A. Goldberg // Diabetes. - 2014. - 63. - Р. 2578 - 2589.

274. Ogawa, S. The heart as an endocrine organ / S. Ogawa, A. J. de Bold // Endocr Connect. - 2014. - 3(2). - P. R31-R44. - Doi : 10.1530/EC-14-0012.

275. Metabolic syndrome: is equine disease comparable to what we know in humans? / A. Ertelt, A.-K. Barton, R. R. Schmitz, H. Gehlen // Endocr. Connect. - 2014. - 3(3). - P. R81-R93. - Doi : 10.1530/EC-14-0038.

276. Study of serum apelin and its relation to obesity-associated hypertension / S. N. Assaad, A. A. El-Aghoury, E. M. El-Sharkawy et al. // Egypt J Obes Diabetes Endocrinol. - 2015. - 1. - Р. 28-35.

277. Apelin, a newly identified adipokine up-regulated by insulin and obesity / J. Boucher, B. Masri, D. Daviaud. - Endocrinology. - 2005. - 146(4). - Р. 1764-1771.